Trial · NCT00855595
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) | Baseline and Week 2 | NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) |
| Secondary | Number of Inflammatory Lesions at Weeks 2, 4, 6, 8 and 12 (LOCF) | Week 2, 4, 6, 8 and 12 | |
| Secondary | Nominal Change From Baseline in IL Count at Weeks 4, 6, 8 and 12 (LOCF) | Baseline and Week 4, 6, 8 and 12 | NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) |
| Secondary | Percent Change From Baseline in IL Count at Weeks 2, 4, 6, 8 and 12 (LOCF) | Baseline and Week 2, 4, 6, 8 and 12 | NOTE: Negative mean values represent an improvement (decrease of inflammatory lesions) |
| Secondary | Percentage of Participants With at Least a 25%, 50%, or 75% Improvement in Facial IL Counts From Baseline to Weeks 2, 4, 6, 8 and 12 (LOCF) | Baseline and Weeks 2, 4, 6, 8 and 12 | |
| Secondary | Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at Weeks 2, 4, 6, 8 and 12 (LOCF) | Weeks 2, 4, 6, 8 and 12 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information) / Therapeutic success is defined as an IGA score of clear or minimal (0 or 1). |
| Secondary | Percentage of Participants With IGA Based Patient Response at Weeks 2, 4, 6, 8 and 12 (LOCF) | Weeks 2, 4, 6, 8 and 12 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information) / Patient response is defined as an IGA score of clear, minimal, or mild (0, 1, or 2) |
| Secondary | Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 2 | At Week 2 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). |
| Secondary | Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 4 | At Week 4 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). |
| Secondary | Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 6 | At Week 6 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). |
| Secondary | Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 8 | At Week 8 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). |
| Secondary | Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Week 12 | At Week 12 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3 - Mild to moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe (refer to Detailed Description field in Protocol section for more information). |
| Secondary | Investigator Rating of Overall Improvement at End of Study (Week 12) | Week 12 | |
| Secondary | Patient Rating of Overall Improvement at End of Study (Week 12) | Week 12 | |
| Secondary | Patient Opinion of Cosmetic Acceptability at End of Study (Week 12) | Week 12 | |
| Other | Patient Opinion of Local Tolerability | Week 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00855595/registered